Hormonal
Among specific GLP-1 receptor agonists, liraglutide and dulaglutide show a statistically significant increase in the risk of overall thyroid disorders, whereas semaglutide, lixisenatide, and exenatide do not show a significant effect.
Not all GLP-1 medications affect the thyroid equally. If you are concerned about thyroid health, liraglutide and dulaglutide have shown a statistically significant increase in overall thyroid disorders in large trials, whereas semaglutide, lixisenatide, and exenatide have not shown this significant risk. Discuss these differences with your provider when choosing a specific agent.
Among all 45 enrolled trials, 18 trials including 24787 patients used liraglutide... increased the risk of overall thyroid disorders by 37% (RR 1.37, 95% CI 1.01-1.86)... dulaglutide significantly increased the incidence of overall thyroid disorders by 96% (RR 1.96, 95% CI 1.11-3.45)... no effect against overall thyroid disorders was found for other GLP-1 receptor agonists [semaglutide, lixisenatide, exenatide, albiglutide].
Why this rating
Based on subgroup analysis of RCTs; however, the number of studies for some agents (e.g., dulaglutide) was small (5 trials), reducing certainty.
Source
Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
Weiting Hu et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.927859
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →